GeneTex to launch new Hypoxia antibody

Hypoxia is a physiological state with reduced oxygen levels that impacts metabolism, angiogenesis, vasodilation and erythropoiesis through the HIF1a transcription factor.

Hypoxia and the subsequent accumulation of HIF1a will contribute to the pathophysiology of multiple diseases including cancer, pulmonary hypertension, myocardial and cerebral ischemia, congenital heart disease and chronic obstructive pulmonary disease.

GeneTex US sales and marketing director Dr. Stephen Kendall said HIF1a is a target for biomedical research but many of the antibodies that are currently on the market have been plagued by specificity and stability issues.

"GeneTex’s new HIF1a antibody can withstand multiple freeze/thaw cycles without losing its sensitivity," Kendall added.

The new antibody has been fully validated for immunocytochemistry/immunofluorescence, immunoprecipitation and western blotting applications, according to GeneTex.